D
espite considerable improvements, heart allograft rejection remains a major problem, leading to graft deterioration and loss and increased mortality, morbidity, and costs. These factors make heart allograft rejection a key target for further progress. 1 As the incidence of T cell-mediated rejection has decreased, 1,2 attention has focused on antibody-mediated rejection, which is mediated by circulating anti-HLA donor-specific antibodies (DSA). 3, 4 Over the past decade, antibody-mediated rejection of heart allografts has been increasingly acknowledged, either in the early period in sensitized patients or, more often, in a lateonset form leading to chronic allograft deterioration and graft loss. 3, [5] [6] [7] [8] Although the ISHLT Consensus (International Society for Heart and Lung Transplantation) has taken important steps to improve the pathological diagnosis of antibody-mediated rejection (pAMR), an important gap remains in terms of the pathophysiology of antibody-mediated heart rejection and how detection of activity, injury degree, and stage could be improved, as highlighted by the American Heart Association in 2015. 9 In the quest for precision medicine, 10 diagnosis of antibody-mediated rejection needs more support, given the complexity of this disease and the inherent limitations of the existing system that relies on conventional histological assessments. Although noninvasive gene profiling methods such as blood testing can be useful to screen for T cell-mediated rejection (Allomap), 11 they were developed in an era that did not recognize the importance of antibody-mediated rejection. In addition, despite their usefulness in screening stable heart transplant patients, with the potential for decreasing the number of unnecessary endomyocardial biopsies (EMBs), blood gene profiling approaches cannot address the mechanisms of antibodymediated rejection, including the biological processes operating in the rejection allografts, nor do they precisely define disease activity or disease stage. One of the best prospects is transcript-level measurements in tissue from well-defined cohorts, as illustrated by the experiences in cancer medicine, where such approaches now provide new levels of information [12] [13] [14] [15] and have changed clinical practice. 12, 13, 15 In kidney transplant medicine, molecular profiling strategies using tissue-level gene expression microarrays have shown promise as a new dimension for assessing transplant biopsies, as recently shown by the development of a microarray-based "molecular microscope" diagnostic system. 16 Similar to cancer studies, cohorts with high levels of phenotypic detail are needed to develop a molecular microscope strategy for heart transplant patients as a new dimension in diagnostics and disease understanding, including relevant biological pathways potentially amenable to treatment. 17, 18 In the present study, we analyzed a large and extensively phenotyped multicenter cohort of heart transplant recipients with antibody-mediated rejection who were managed with a standardized clinical protocol. The phenotype included assessment of transcript levels in EMBs, histological injury, and serum immunological monitoring. We hypothesized that integration of tissuelevel transcriptome profiles of the specific allograft injury induced by anti-HLA antibodies in heart transplants with in vitro studies of human cell panels may aid in the mapping of the key pathways involved in antibody-mediated heart rejection, providing a new dimension to increase accuracy in the determination of antibody-mediated rejection disease activity, injury, and staging.
METHODS Multidisciplinary Network
This study involved the Paris Translational Research Center for Organ Transplantation http://www.paristransplantgroup. org/ and the Alberta Transplant Applied Genomics Center in Edmonton, AB, Canada. This multidisciplinary collaborative transatlantic research project aims to advance knowledge of heart transplant rejection. This network includes experts in cardiology, heart transplantation surgery, transplant immunology, basic science, histopathology, microarrays, computational science, and biostatistics.
Participants
We prospectively screened 617 patients who underwent heart transplantation in 4 French referral centers (Hôpital Georges Pompidou and Pitié Salpétrière in Paris, Hôpital Laennec in
Clinical Perspective
What Is New?
• In this study, we monitored patients with heart transplants for antibody-mediated rejection using multidimensional tissue-based gene expression profiling approach.
• We report that antibody-mediated rejection has a distinct molecular pattern of injury driven mainly by natural killer cell burden, endothelial cell activation, macrophage burden, and interferon-γ-inducible effects.
• With this approach, we were able to accurately determine the presence of antibody-mediated rejection in the endomyocardial biopsy specimens, which correlates with degree of injury and disease activity.
• This is the first study reading endomyocardial biopsy specimens from a molecular approach and characterizes potential mechanisms of antibody-mediated rejection.
What Are the Clinical Implications?
• The current gold standard of heart rejection is histopathological evaluation. Therapies for antibodymediated rejection are of unknown efficacy.
• This study illustrates the clinical potential of a tissuebased analysis of gene transcripts to refine diagnosis of heart transplant rejection.
Nantes, and Hôpital Charles Nicolle in Rouen) between January 1, 2006, and January 1, 2011. Among them, 68 patients (11%) had a diagnosis of antibody-mediated rejection in 86 biopsies. After exclusion of 15 biopsies owing to a lack of suitable material for microarray analysis, 55 patients with 71 biopsies were included as the study sample. These were compared with a control group of 55 patients (71 biopsies) without antibodymediated rejection. Patients were matched on the following criteria: time of transplantation, recipient age, donor age, cold ischemia time, time from transplantation to index biopsy, and maintenance immunosuppressive regimen. Conventional graft histology, immunohistochemistry and assessment of transcript abundance in the EMB by microarray, and anti-HLA DSA assessments in serum taken at the time of biopsy were performed on the samples from all antibody-mediated rejection and control patients. The transplantation allocation system was identical for the 4 centers and followed the rules of the French National Agency for Organ Procurement (Agence de la Biomédecine). We used an additional independent validation sample of 98 biopsies from heart recipients transplanted in Edmonton, AB, Canada from June 1, 2007, to June 1, 2010, which were processed for microarray analysis (see Table I in the online-only Data Supplement for patient characteristics). All of the transplants were ABO compatible and had negative immunoglobulin G-, T cell-, and B cell complement-dependent cytotoxicity cross-matching at the time of transplantation. 
Clinical Data
The clinical data and baseline characteristics were retrieved from the Agence de la Biomédecine CRISTAL database. 19 The CRISTAL database networks have been approved by the National French Commission for Bioinformatics Data and Patients' Liberty (registration No. 363505, validated April 3, 1996) . Codes were used to ensure strict donor and recipient anonymity, and informed consent was obtained from the participants. Biopsy biobanking was approved by Comité de Protection des Personnes Île de France II (projet de recherche 2014-12-26, Institutional Review Board registration 00001072). Molecular biopsy profiling in patients was approved by French Comité Consultatif sur le Traitement de l'Information en matière de Recherche dans le domaine de la Santé (registration No.15.871).
Definition of Antibody-Mediated Rejection of Heart Allografts
Histology of EMBs was independently assessed by 2 expert pathologists (J.P.D.V.H. and P.B.). The pathologists were blinded to the clinical information and circulating anti-HLA DSA status. Antibody-mediated rejection was defined according to the most recent recommendation of the pathology task force of the International Society for Heart and Lung Transplantation (ISHLT 2013) 20 and considered histopathological findings with 
Immunohistochemistry
We analyzed the deposition of the complement split product C4d in the paraffin sections of the EMBs using an immunoperoxidase method and an anti-C4d antibody (Cliniscience). We also assessed the presence of allograft capillary-infiltrating macrophages using an anti-CD68 (DakoCytomation) antibody as previously described. 22 The natural killer (NK) cells in frozen EMB sections were stained with NKp46/NCR1 immunohistochemistry (clone 195314, R&D Systems Europe). For CD16a immunohistochemistry (clone GRM1, Harlan Seralabd), EMB paraffin sections were used. A 3-step immunoperoxidase method was performed as previously described. 23 
RNA Extraction and Microarray Analyses
All biopsies were processed for microarray analysis as previously described. 24 One biopsy bite was immediately placed in a dry tube and stored at −80°C. RNA extraction, labeling, and hybridization to the HG-U219 GeneChip arrays (Affymetrix) were performed according to the manufacturer's protocols (www.affymetrix.com). The microarrays were scanned, and .cel files were generated with GeneChip Operating Software 1.4.0 (Affymetrix). (The term transcript is used synonymously with probe set signal measurement.) The microarray data files for 142 biopsies were normalized with Robust Multiarray Averaging in Bioconductor. We used pathogenesis-based transcript sets (PBTs) reflecting biological processes with known relevance to the pathogenesis of organ rejection: NK cell transcripts (NK), endothelial DSA-selective transcripts (DSASTs), interferon-γ (IFNG) response transcripts (GRITs), macrophage transcripts, an antibody-mediated rejection gene set, and heart parenchymal transcripts (HTs), as previously described. 18 The gene list of each PBT is available at http://atagc.med.ualberta. ca/Research/GeneLists/Pages/default.aspx.
Detection and Characterization of Anti-HLA DSA All patients were tested for the presence of circulating anti-HLA DSA in banked serum samples taken at the time of biopsy. The presence of circulating DSA against HLA-A, HLA-B, HLA-Cw, HLA-DR, HLA-DQ, and HLA-DP was determined with single-antigen bead assays (One Lambda, Inc) on a Luminex platform. Beads with a normalized mean fluorescence intensity (MFI) >500 arbitrary units were judged positive as previously described. 25 HLA typing of the transplant recipients was performed (Innolipa HLA Typing Kit, Innogenetics). Donor HLA typing for HLA-Cw and HLA-DP was performed only if the recipients had circulating anti-HLA-Cw and/or anti-HLA-DP. Tissue typing was conducted using the microlymphocytotoxicity technique with One Lambda INC and tissue-typing trays; traditional molecular biology controls were included.
Pathway Analysis
The transcripts were analyzed with Ingenuity Pathway Analysis (Ingenuity Systems, www.ingenuity.com), with a focus on the canonical pathways. Ingenuity Pathway Analysis Path Designer and the grow function were used to determine the associations between antibody-mediated rejection-associated transcripts.
Expression of the Transcripts in Cultured Cells
We isolated peripheral blood mononuclear cells from the whole blood of healthy volunteers by density gradient centrifugation with Ficoll and then purified the following cell populations for expression analysis on HG-U133 Plus 2.0 GeneChip arrays as previously described 26 bright NK cells, suggestive of a cytolytic phenotype. 28 As expected, the majority (average, 96.1%) of NK cells in whole blood showed a cytotoxic phenotype (CD56 dim ). 
Statistical Analysis
We report means and standard deviations to describe continuous variables, with the exception of the MFI; for this variable, we used median and range. We compared the means and counts with the Student t test and χ 2 test, respectively. To find the genes with the highest differential expression between the patients with antibody-mediated rejection and the other patients, we compared the means using limma bayesian t test.
30 P values were corrected for multiple comparisons with the false discovery rate. The Jaccard index was used to quantify the overlap between the selected antibody-mediated rejection genes in the principal and validation sets. 31 Gene set enrichment analysis was also performed. 32 We performed unsupervised methods to visualize the differences between the antibody-mediated rejection and non-antibody-mediated rejection biopsies, including principal component analysis, using the following PBT scores: NKs, DSASTs, GRITs, macrophage transcripts, antibody-mediated rejection molecular gene set, and HTs. The number of probe sets in the PBTs is as follows: NK genes, n=11; DSAST genes, n=69; GRIT genes, n=114; macrophage transcript genes, n=160; antibody-mediated rejection gene set, n=97; and HT genes, n=2434. The PBT score represents the geometric mean of the fold changes (relative to the controls) of all the probe sets in a PBT. Expression of the antibody-mediated rejection-associated genes in human cell cultures was assessed with standardized z scores of the probe set signals. Principal component analysis was performed with the dudi.pca function of the ade4 package in R. Statistical significance was set at P≤0.05. All tests were 2 sided. Gene set respective importance for chronic allograft vasculopathy (CAV) grade and patient death was studied with random forest survival analysis (RFS). RFS is known to have good performance for small sample size and in some situations outperforms the traditional stepwise Cox model. 33 RFS is a nonparametric machine learning method developed by Ishwaran et al 33 that is an extension of random forest to right-censored survival settings. Our RFS analyses were generated by creating 2000 trees; each tree was developed with the use of a bootstrap sample of the original data set. At each branch, a random set of variables are chosen as candidates to split the branch into 2 other branches, and the variable maximizing the log-rank statistic using 3 randomly selected split points was used for splitting. Splitting of branches to create the tree continues as long as possible until terminal branches have no fewer than 3 events. 34 We calculated variable importance, which measures the increase in prediction error when the variable is "noised up." 35 A positive value indicates a predictive covariate. RFS was performed with the rfsrc function from randomForestSRC in R. Unless otherwise indicated, all statistical analyses were performed with STATA 14.0 software (StataCorp) and R (version 3.2.1, R Foundation for Statistical Computing).
RESULTS

Patient Characteristics
Of the 617 patients who underwent heart transplantation in 4 French referral centers (Georges Pompidou, Pitié Salpétrière, Laennec, and Charles Nicolle hospitals) between January 1, 2006, and January 1, 2011, and were screened for antibody-mediated rejection, we identified 71 antibody-mediated rejection heart transplant biopsies from 55 patients who were matched to 71 control biopsies without antibody-mediated rejection from 55 patients. The patients were similar with regard to the recipient and donor ages, sex, cold ischemia time, pri-mary heart disease, induction therapy, maintenance immunosuppression, and HLA matching. The time between transplantation and EMB, type of EMB (cause or protocol), left ventricular function, and CAV grade were similar between the 2 groups. None of the patients had ongoing sepsis or a cytomegalovirus infection at the time of EMB (Tables 1 and 2 ).
The antibody-mediated rejection group was graded according to the pAMR 2013 ISHLT classification and included 20 pAMR1(I + ) cases (28%), 24 pAMR1(H + ) cases (34%), and 27 pAMR2/3 cases (38%). A total of 32 of the 71 pAMR biopsies (45%) showed capillary deposition of complement fraction C4d, and 51 of 71 (72%) displayed intravascular activated mononuclear cells in the capillaries, with 35 of 51 (69%) showing CD68-positive staining in macrophages. The phenotypes of the antibody-mediated rejection cases are depicted in Figure 1 and Tables 1 and 2 . The nonantibody-mediated rejection group comprised both normal EMBs (n=42, 59%) and EMBs with T cell-mediated rejection (n=29, 41%) to control for potential overlapping genes between the antibody-mediated rejection and T cell-mediated rejection groups. The distribution of T cell-mediated rejection grades according to the ISHLT 2005 classification was 1R (n=13, 45%), 2R (n=13, 45%), and 3R (n=3, 10%). The anti-HLA DSA assessment at the time of index EMB revealed that 59 of 71 patients (83%) from the antibody-mediated rejection group had anti-HLA DSA compared with 11 of 71 (15%) in the non-antibody-mediated rejection group (P<0.0001). The mean immunodominant DSA MFI was 2940±900 in the antibody-mediated rejection group compared with 870±500 in the non-antibody-mediated rejection group (P<0.0001). Among the DSA-positive patients with antibody-mediated rejection, 24 (41%) had class I DSA and 35 (59%) had class II DSA.
Molecular Landscape of Heart AntibodyMediated Rejection
Identification of Heart Antibody-Mediated RejectionRelated Gene Expression Patterns
We compared the gene expression patterns in biopsies with antibody-mediated rejection and those without antibody-mediated rejection (Figure 2 ). Among the 9.954 interquartile range-filtered probe sets, 1836 were significantly changed at a false discovery rate of 0.05. The top genes identified were the NK-associated genes CCL4, FCGR3A, CX3CR1, and GNLY; the endothelial genes GGH, PLA1A, RAPGEF5, ROBO4, and ECSCR; the IFNGinducible genes CXCL9, CXCL10, CXCL11, HLA-DQA1, and HLA-DB1; and the monocyte-macrophage genes LYZ, LST1, CSF2RB, and MS4A7. The top 50 probe sets that were differentially expressed between these groups are shown in Table 3 .
Relationship of the Heart Antibody-Mediated RejectionAssociated Transcripts to Their Biological Function: NK Cell-CD16A Signaling, Endothelial Injury, and IFNG Effects
We used the curated Ingenuity Pathway Analysis canonical pathways to glean insight into the biology underlying antibody-mediated rejection and examined the 300 transcripts that were most significantly increased in the antibody-mediated rejection groups. The top 30 overrepresented canonical pathways were aligned by P value, as shown in Table II 
Heart Antibody-Mediated Rejection-Associated Transcripts in Cultured Cells: Principal Effector Cells Involved in Antibody-Mediated Rejection and Evidence for Infiltrating NK Cells in Allograft
The top nonredundant antibody-mediated rejectionselective transcripts expressed in the heart allograft tissue were studied in a panel of primary human cells, including effector CD8 + and CD4 + T cells, NK cells, B cells, monocytes, macrophages, and unstimulated and IFNG-treated human vascular endothelial cells. All cells in the panel were purified from healthy volunteers, and none were exposed to DSA derived from any of the patients. On the basis of the highest relative expression in cell cultures (probe set signal z score), we determined that the top antibody-mediated rejection-selective transcripts were expressed mainly by NK cells (FCGR3A/3B), NK cells after recent CD16 stimulation (CCL4 and FCGR3A/3B), and NK cells recruited at least in part through the CX3CL1-CX3CR1 pathway (CX3CR1); myeloid cells (MS4A7, LST1, CTSS, and TYROBP); the endothelium under IFNG effects (CXCL11 and PLA1A); and transcripts representing general IFNG effects, including CXCL9-11, FCER1G, and GCH1, and HLA-associated transcripts ( Figure 3) . The associations found within our cell panel analysis corroborate the canonical pathways identified above.
The identification of effector cell transcripts in heart biopsies with antibody-mediated rejection through ca-nonical pathway analysis and on the cell panel was further confirmed through immunohistochemistry in the biopsies. In addition to the CD68 + myeloid cells (Figure 1 ) in the heart antibody-mediated rejection group, the pAMR1(H 
Intragraft Gene Expression Profiling Identifies Antibody-Mediated Rejection and Classifies the Degree of Injury
We first tested whether the identified PBTs expressed in the EMBs could discriminate between antibody-mediated rejection and non-antibody-mediated rejection in Figure 4A ). We also evaluated the association of the expression of the 6 gene sets with the ISHLT pAMR grades and found a positive correlation with increasing pAMR ISHLT grades ( Figure 4B ). Principal component analysis showed correlation of the relevant gene sets with ISHLT pAMR grades. Unsupervised principal component analysis failed to separate pAMR0 from pAMR1(I + ), and the pAMR1(H + ) cases showed significant molecular overlap with full-blown pAMR2/3 cases ( Figure 4D ). Figure 4C shows the correlation of each of the constituent parts making up the principal component analysis with the overall principal component (PC) 1 and 2 scores. It shows the direction of the NK, DSAST, and antibody-mediated rejection gene set vectors representing the driving force to increasing pAMR grade, confirming the dominant role for the NK genes, endothelial genes, and macrophage genes ( Figure 4D ). The causes of patient death are detailed in Table  III in the online-only Data Supplement. The time from EMB to patient death in the overall cohort and according to injury phenotypes is depicted in Figure III in the online-only Data Supplement. Using a random forest procedure, we identified that the gene sets most correlated with patient death were DSASTs, GRITs, and HTs (error rate, 0.13; (Figure 5A ), whereas the gene sets most correlated with CAV grade at the time of biopsy were DSASTs, HTs, and NK B cells (error rate, 0.23; Figure 5 B ). After histopathological antibody-mediated rejection diagnosis and circulating DSA status were entered into the random forest model, the heart antibody-mediated rejection gene sets remained independently associated with CAV and patient death ( Figure IV 
External Validation and Sensitivity Analyses
External Validation
The external validation set was composed of 98 EMBs (27 with histological diagnosis of antibody-mediated rejection and 71 without) performed between June 2007 and June 2010 in heart recipients transplanted in Edmonton, AB, Canada. Baseline patient characteristics of the external validation set are detailed in Table I in the online-only Data Supplement. We first compared global transcript changes in conventionally diagnosed antibody-mediated rejection with non-antibody-mediated rejection biopsies in the discovery and validation cohorts. The fold change and the association strength of the top antibody-mediated rejection transcripts in the discovery cohort were strongly correlated with those in the external validation cohort ID indicates identification; IFNG, interferon-γ; and NK, natural killer. Transcripts are ranked on the basis of the strength of the association with antibodymediated rejection (as presented in Figure 1A ), P value (single-pass bayesian t test), and interquartile range-filtered genes (n=9.953). A, Relationship between gene sets reflecting the natural killer (NK) burden, endothelial activation, interferon-γ (IFNG) activity, macrophage burden, antibody-mediated rejection transcripts, heart parenchymal transcripts, and antibody-mediated rejection diagnosis (pAMR + , n=71) vs controls (pAMR0, n=71). B, Intragraft expression of the pathogenesis-based transcripts and their relationship with heart International Society for Heart and Lung Transplantation antibody-mediated rejection grade. C, Unsupervised principal component (PC) analysis of heart allograft rejection phenotypes based on molecular profiles. The dudi plot (C) is made from NK cell transcripts (NK), endothelial donor-specific antibody-associated transcripts (eDSASTs), IFNG response transcripts (GRITs), macrophages transcripts (QCMATs), antibody-mediated rejection gene set (ABMR), and heart parenchymal transcripts (HTs). The center of the ellipse represents the gravity center of the point cloud. The ellipse construction is based on the fact that the probability of being in the ellipse is equal to P=1−exp[− (0.5)×k^2]. Here, k =1.5 so P=0.67 (≈70%); ie, the ellipse contains 70% of the individuals of the group. D, The correlation circle interpreting the meaning of the PC axes shows that the antibodymediated rejection phenotype is driven mainly by NK genes and endothelial activation genes, as well as macrophage genes and IFNG genes. The PC analysis correlation map (D) is the same. All the transcripts included in these gene sets are detailed in our website http://atagc.med.ualberta.ca/Research/GeneLists/Pages/default.aspx. Table IV in the online-only Data Supplement). In the Paris and Edmonton sets, the greatest fold increase was for IFNG-inducible chemokine (C-X-C motif) ligand 11 (CXCL11), and the most significant P value was obtained for the NK genes (CCL4, CCL4L1, FCGR3A; Figure V in the online-only Data Supplement). We also assessed the top 200 probe sets distinguishing antibody-mediated rejection from non-antibody-mediated rejection in the Paris training set using a bayesian t test and the performance of those same 200 probe sets in the Edmonton external validation set ( Figure 6 ). We confirmed that there was a highly significant overlap of the antibody-mediated rejection-associated genes in the principal and validation cohorts (for the top 200 antibody-mediated selective genes, Jaccard index = 0.07, hypergeometric P value =10E −33 ). The gene set enrichment analysis showed that the top 200 antibody-mediated rejection genes identified in the Paris principal cohort were also significantly enriched in the external Edmonton validation cohort (gene set enrichment analysis, P=0.01). Finally, we confirmed using Figure 5 . Association of NK cell transcripts (NKs), endothelial donor-specific antibody-associated transcripts (eDSASTs), interferon-γ response transcripts (GRITs), macrophages transcripts (QCMATs), antibody-mediated rejection gene set (ABMR), and heart parenchymal transcripts (HTs) with patient survival (A) and presence of chronic allograft vasculopathy (CAV) at the time of biopsy (B) by random forest analysis.
receiver-operating characteristic curve analysis that 6 gene sets discriminated patients with antibody-mediated rejection from patients without antibody-mediated rejection ( Figure VI in the online-only Data Supplement). Taken together, these results confirm the robustness of the antibody-mediated rejection-selective genes identified in the primary analyses, the consistency of the antibodymediated rejection disease molecular architecture, and the accuracy of the classification of antibody-mediated rejection.
Sensitivity Analysis
In the Paris cohort (discovery cohort), we compared the respective gene sets according to the type of induction therapy and found decreased gene expression levels for DSAST, NK, and antibody-mediated rejection score in patients who received thymoglobulin (n=94) compared with patients who received basiliximab (n=16; Figure VII in the online-only Data Supplement). We also analyzed gene expression in antibody-mediated rejection cases occurring in the first year after transplantation (n=34, 48%) compared with antibody-mediated rejection occurring after 1 year after transplantation (n=37, 52%) and did not find differences in gene expression related to timing of rejection ( Figure 
DISCUSSION
In the present study, we evaluated a large, extensively phenotyped multicenter cohort of heart transplant recipients with antibody-mediated rejection and defined, for the first time, the molecular landscape of heart antibody-mediated rejection. We report that it is characterized by NK cell transcripts, endothelial cell/angiogenesis genes, IFNGinducible genes, and monocyte genes. We found that the antibody-mediated rejection-selective genes were robustly expressed across 2 distinct heart transplant populations. We also identified the relationship between expression of genes involved in heart antibody-mediated rejection and specific cell types, including endothelial cells, NK cells, and monocytes/ macrophages, using human immune effector cells cultured in vitro. Finally, we showed that the intragraft gene profiling strategy classified antibody-mediated rejection with high accuracy and was correlated with disease activity and ISHLT pAMR stage.
Our studies suggest that NK cells and monocytes/ macrophages are key immune mediators in heart antibody-mediated rejection. CD68 + monocytes have long been associated with heart antibody-mediated rejection, 5, 36 which explains their dominant representation in the top transcripts. The degree of IFNG effects on endothelial cells of the allograft was not previously appreciated (as exemplified by CX3CL1, PLA1A, and CXCL11), nor was the role of myeloid cell transcripts (CXCL10, FCER1G) indicative of NK cell CD16a engagement. 37 CCL4 upregulation is also indicative of IFNG effects on myeloid cells, but its transcription and secretion are downstream of CD16A engagement on NK cells (manuscript in preparation). Thus, CCL4 may serve as a summative marker of the overall degree of antibody-mediated rejection-related immune cell activity, CD16a engagement, and IFNG effects on myeloid cells.
The identification of such selective chemokine networks in our study helps to explain the enrichment of monocytes and NK cells, setting the scenario for future therapeutic efforts aimed at DSA-coated targets. The IFNG-inducible chemokines CXCL10, CXCL11, and CX-3CL1 help recruit and retain NK cells.
38 CD16a engagement on NK cells leads to CCL4 production and subsequent monocyte recruitment, which further amplifies the effects of IFNG. IFNG production from NK cells also increases FCER1G expression on myeloid cells, enhancing their ability to stimulate Fc receptors. CSF2RB expression also responds to IFNG on myeloid cells, making these cells more receptive to granulocyte-macrophage colony-stimulating factor produced by NK cells after CD16a stimulation, thus enhancing their cytotoxic and proinflammatory potential. 39 An important implication of the present study is the potential of intragraft molecular assessments for measuring antibody-mediated rejection disease activity, staging, and heterogeneity. Our study not only shows a global increase in the expression of antibody-mediated rejection-selective genes with increasing ISHLT pAMR grade but also clarifies the degrees of injury inside the pAMR ISHLT categories, particularly in the pAMR1 category, which is denoted as suspicious for antibodymediated rejection. 4 We found that a substantial proportion of pAMR1(I + ) cases (12 of 20, 60%) are molecularly inactive (with molecular features similar to biopsies without antibody-mediated rejection); in contrast, most pAMR1(H + ) cases (19 of 24, 79%) displayed a molecular profile (NK burden, endothelial activation, macrophage burden, and IFNG) similar to full-blown pAMR2/3 cases. It is now increasingly recognized that intravascular macrophages without complement deposition [pAMR1(H + )] represent mainly an indolent and subclinical form of antibody-mediated rejection 22 with potential long-term detrimental consequences for the allograft, manifested as development of accelerated CAV. 3, 7 However, there is still no unified approach to activity and degree of injury in the pAMR1 category and no validated treatment strategy for pAMR1 (Treatment recommendations range from no therapeutic intervention to increased surveillance or maintenance immunosuppression optimization). 9 Currently, only patients with pAMR grades ≥2 receive antibody-targeting treatments 9 ; however, our results suggest that pAMR1(H + ) patients with a high level of antibody-mediated rejection-related transcripts may warrant specific therapeutic interventions.
Strengths and Limitations
We used a unique approach to study heart transplant rejection by extensively phenotyping allografts by classic histology/immunohistochemistry in addition to characterization of circulating anti-HLA antibodies at the time of biopsy and determining the gene expression and specific staining patterns in effector cells in the biopsy and in vitro human cell cultures. This approach provided mechanistic insights and the potential relevance of a heart molecular microscope approach. Because our main goal was to identify antibody-mediated rejectionspecific gene sets, we designed this study to include antibody-mediated rejection cases (ISHLT pAMR1/2/3) that were prospectively diagnosed in 4 referral centers, thus representing the spectrum of antibody-mediated rejection clinical situations encountered in the modern era of heart transplantation. Our research strategy also included a matched control group comprising normal biopsies and T cell-mediated rejection cases to eliminate potentially overlapping genes shared between antibodymediated rejection and T cell-mediated rejection. Despite this careful selection as part of our study design and the validation of our results in an external North American heart transplant cohort, our results need to be tested in unselected prospective cohorts of heart recipients.
The present study describes the respective contribution of gene sets in the prognosis and prediction of patient death and the presence of CAV at the time of biopsy. Using a random forest procedure, we identified that the gene sets most associated with patient death were DSASTs, GRITs, and HTs, and the most important gene sets correlated with CAV grade at the time of biopsy were DSASTs, HTs, and NK B cells. Although promising, these results have to be interpreted in the context of the present study, which was not designed to address outcome parameters. Therefore, these results require further confirmation. Finally, the purpose of this study differs from most investigations of peripheral noninvasive biomarkers for the detection of rejection. Peripheral gene profiling has been tested in the setting of stable heart allograft monitoring to refine the criteria for situations in which a screening biopsy would be mandatory. 11 Our study proposes an integrative approach that specifically allows researchers/clinicians to connect allograft phenotypes with tissue-specific injury, 'omics, histology, and antibody screening, which is an unmet need to improve the current gold standard for the detection of antibody-mediated rejection, histopathology.
Conclusions
Using a combination of multidimensional molecular assessment, extensive phenotyping of allograft biopsies, and precise characterization of anti-HLA antibodies and cellular models, we demonstrate that antibody-mediated rejection in heart transplantation is driven mainly by the NK burden, genes associated with endothelial activation, macrophage genes, and IFNG effects.
Tissue-level molecular measurements for these specific PBTs accurately classify antibody-mediated rejection, reclassify pAMR1 cases, and correlate with degree of injury, disease activity, and stage, thus representing changes at the molecular level that could complement the current ISHLT pAMR system.
Because current therapies in heart antibody-mediated rejection are of unknown efficacy, this molecular approach has potential to guide trials in defining the effects of therapy targeted at antibody-mediated rejection and mapping key pathways involved in antibody-mediated rejection. Such tissue-level molecular analysis will be useful for designing and testing novel therapeutic interventions and improving precision medicine in heart transplant diagnostics. 40, 41 
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